Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor
Open Access
- 3 March 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1124111
Abstract
Prostate cancer remains the most prevalent cancer among men worldwide. This cancer is hormone-dependent; therefore, androgen, estrogen, and their receptors play an important role in development and progression of this disease, and in emergence of the castration-resistant prostate cancer (CRPC). Galectins are a family of β-galactoside-binding proteins which are frequently altered (upregulated or downregulated) in a wide range of tumors, participating in different stages of tumor development and progression, but the molecular mechanisms which regulate its expression are still poorly understood. This review provides an overview of the current and emerging knowledge on Galectin-3 in cancer biology with focus on prostate cancer and the interplay with estrogen receptor (ER) signaling pathways, present in androgen-independent prostate cancer cells. We suggest a molecular mechanism where ER, Galectin-3 and β-catenin can modulate nuclear transcriptional events, such as, proliferation, migration, invasion, and anchorage-independent growth of androgen-independent prostate cancer cells. Despite a number of achievements in targeted therapy for prostate cancer, CRPC may eventually develop, therefore new effective drug targets need urgently to be found. Further understanding of the role of Galectin-3 and ER in prostate cancer will enhance our understanding of the molecular mechanisms of prostate cancer development and the future treatment of this disease.Keywords
This publication has 85 references indexed in Scilit:
- The significance of galectin-3 as a new basal cell marker in prostate cancerCell Death & Disease, 2013
- The Effects of 17β-estradiol in Cancer are Mediated by Estrogen Receptor Signaling at the Plasma MembraneFrontiers in Physiology, 2011
- Cleavage of galectin‐3 by matrix metalloproteases induces angiogenesis in breast cancerInternational Journal of Cancer, 2010
- Dynamics of galectin-3 in the nucleus and cytoplasmBiochimica et Biophysica Acta (BBA) - General Subjects, 2010
- Regulation of Prostate Cancer Progression by Galectin-3The American Journal of Pathology, 2009
- Galectin-3 Mediates Nuclear β-Catenin Accumulation and Wnt Signaling in Human Colon Cancer Cells by Regulation of Glycogen Synthase Kinase-3β ActivityCancer Research, 2009
- RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumorsEndocrine, 2008
- Involvement of decreased Galectin‐3 expression in the pathogenesis and progression of prostate cancerThe Prostate, 2007
- Repression of the Antiapoptotic Molecule Galectin-3 by Homeodomain-Interacting Protein Kinase 2-Activated p53 Is Required for p53-Induced ApoptosisMolecular and Cellular Biology, 2006
- Galectins as modulators of tumour progressionNature Reviews Cancer, 2005